血清アディポネクチン値に基づくメタボリックシンドロームの発症予測 : 第263回徳島医学会学術集会シンポジウムより

A rapid increase in the number of people who develop metabolic syndrome（MetS）is drawing much attention, since MetS-associated complications, such as cardiovascular diseases, are not only life-threatening, but also remarkably impair the quality of life for those who have MetS. Thus, developing a method to identify those who are at risk of developing MetS is crucial to maintain their quality of life and reduce the burden on society to provide care, since such a method will enable early intervention for those who may be at risk and prevent them from developing MetS. Here we report from two prospective cohort studies that the cut-off value of serum total adiponectin level for managing the risk of developing MetS is６．２μg／ml in male and６．５μg／ml in female. Subjects with total adiponectin level equal to or lower than the cut-off value developed MetS more rapidly than did those with total adiponectin level higher than the cut-off value. A follow up study validated the cutoff value of total adiponectin level in both male and female. Furthermore, evaluating the risk of developing MetS in future by adiponectin level successfully identified those who are at risk among people who are not obese by their anthropometric measurements. These results provide evidence that adiponectin level is able to serve as a biomarker for predicting future onset of MetS.